Generics 19

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Piperaquine phosphate manufacturers

19 products found

Filters

19 products found

dihydroartemisinin + piperaquine phosphate

Tablets 40 mg + 320 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #13225
It is an Indian manufacturer that is active in 40+ countries. They are in this line of business for 85+ years. The company has a more than $150 million turnover. The company manufactures and distributes more than 100 APIs and 200 formulations which is responsible for 25000+ SKUs. Quality control and quality assurance are one of the focus areas for the company.

Manufacturer usually replies in 3 days

dihydroartemisinin + piperaquine phosphate

Tablets 20 mg + 160 mg, 40 mg + 320 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP, TGA
Manufacturer #18120

Manufacturer usually replies in 7 days

dihydroartemisinin + piperaquine phosphate

Oral suspension 20 mg + 160 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP, TGA
Manufacturer #18120

Manufacturer usually replies in 7 days

dihydroartemisinin + piperaquine phosphate

Capsules 40 mg + 320 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Pakistan
GMP approvals
Sri Lanka, Afghanistan, Vietnam, Cambodia, Myanmar
Manufacturer #21102

Manufacturer usually replies in 5 days

dihydroartemisinin + piperaquine phosphate

Tablets 40 mg + 320 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20848

Manufacturer usually replies in 3 days

dihydroartemisinin + piperaquine phosphate

Oral suspension 80 mg + 640 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20848

Manufacturer usually replies in 3 days

dihydroartemisinin + piperaquine phosphate

Tablets 40 mg+320 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19472

Manufacturer usually replies in 4 days

dihydroartemisinin + piperaquine phosphate

Oral suspension 80 m+640 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19472

Manufacturer usually replies in 4 days

dihydroartemisinin + piperaquine phosphate

Tablets 40 mg + 320 mg, 32 mg + 320 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP, WHO
Manufacturer #2303

Manufacturer usually replies in 7 days

dihydroartemisinin + piperaquine phosphate

Tablets 40 mg + 320 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Pakistan
GMP approvals
WHO, Nigeria, Pakistan, Kenya, Uganda, Ghana, Ivory Coast
Manufacturer #21095

Manufacturer usually replies in 6 days

dihydroartemisinin + piperaquine phosphate

Tablets 40 mg+320 mg, 80 mg+640 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19670

Manufacturer usually replies in 8 days

dihydroartemisinin + piperaquine phosphate

Tablets 40mg+320mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
China
GMP approvals
China
Manufacturer #16892

Manufacturer usually replies in 6 days

dihydroartemisinin + piperaquine phosphate

Tablets, orally disintegrating (ODT) 40 mg + 320 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
PICS
Manufacturer #2693

Manufacturer usually replies in 5 days

dihydroartemisinin + piperaquine phosphate

Tablets 40 mg + 320 mg, 80 mg + 640 mg, 20 mg + 160 mg, 120 mg + 960 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
PICS
Manufacturer #2693

Manufacturer usually replies in 5 days

dihydroartemisinin + piperaquine phosphate

Oral suspension 90 mg + 120 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
South Korea
GMP approvals
South Korea
Manufacturer #21840

Manufacturer usually replies in 26 days

dihydroartemisinin + piperaquine phosphate

Tablets 40 mg + 320 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #21238

dihydroartemisinin + piperaquine phosphate

Tablets 40 mg + 320 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Indonesia
GMP approvals
Indonesia
Manufacturer #20684

dihydroartemisinin + piperaquine phosphate

Oral suspension 80 mg + 640 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20427

dihydroartemisinin + piperaquine phosphate

Tablets 40 mg + 320 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20427

Dihydroartemisinin

Dihydroartemisinin or DHA is a semi-synthetic derivative of artemisinin. It is used primarily in the preparation of Artemisinin-derived antimalarial drugs. It cures malaria. While Dihydroartemisinin is the active metabolite in artemisinin compounds it is also sold as a drug in itself. Commercially, it is sold with piperaquine. It has been shown to be similar to Artemether or Lumefantrine. Dihydroartemisinin in combination with piperaquine is sold as Eurartesim and Artekin among several other brands. Hoechst Aktiengesellschaft filed the first patent in 1987, this was followed by a patent filing in the USA by Thornfeldt Carl R in 1987. In 2018, WHO says, worldwide malaria-affected 228 million people, resulting in 405,000 deaths. The key to the treatment is timely intervention before it turns severe and then fatal.

Dosage and forms

Dihydroartemisinin is sold as tablets and injections. In the cases of acute malaria, the initial the recommended adult dose is 120 mg, and this is followed by a maintenance dose of 60 mg, taken daily for another 4 to 6 days.

The cost of Dihydroartemisinin

In India and elsewhere in the developing world this medicine is very cheap. In most countries, a tablet of 200 mg costs less than a cent. The oral suspension costs around USD1 for an 80ml solution.

How does Dihydroartemisinin Work?

Apicomplexans cause Malaria. Plasmodium falciparum residing in red blood cells and contains iron-rich heme-groups. Dihydroartemisinin binds to a large number targets a broad spectrum of proteins in the human cancer cell proteome through heme-activated radical alkylation. Dihydroartemisinin actions cleavage endoperoxide bridges by iron. It does this producing free radicals like hypervalent iron-oxo species, epoxides, aldehydes, and dicarbonyl compounds. These damage biological macromolecules causing oxidative stress in the cells of the parasite. Its production of free radicals, reactive metabolites, and altered membrane transport properties of membranes stop the nutrient flow to the parasite. It is Active against all human malarial parasites, including even the multi-drug resistant Plasmodium falciparum strains.

Finding Dihydroartemisinin Manufacturers and Suppliers:

The process of finding trusted Dihydroartemisinin manufacturers and Dihydroartemisinin suppliers can be made quicker and more accessible by using Pipelinepharma's online the platform, a B2B marketplace that lets you finalize the deals of pharmaceutical products in a matter of a few clicks. Also, it is easy to use the online platform to grow your business opportunities. The robust search engine makes it convenient to search for manufacturers and suppliers of Dihydroartemisinin. The search can be further refined with industry-specific filters such as dossier type, country of origin, GMP approvals, and search criteria for Wholesaler, etc. helping to get in contact with the preferred manufacturer and supplier readily.